Fabry disease Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis

July 01 04:20 2021
Fabry disease Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis

DelveInsight Business Research LLP
Fabry disease Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Fabry disease Market.

Fabry disease Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Fabry disease Market.

The assessment part of the report embraces in-depth Fabry disease commercial assessment and clinical assessment of the Fabry disease pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Fabry disease collaborations, licensing mergers, and acquisition, funding, designations, and other product-related details.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight

Fabry disease Overview

Fabry disease (FD) is a devastating, progressive, inherited condition caused by lysosomal dysfunction linked to chromosome X and mutations in the GLA gene located in chromosome Xq22.1 which encodes the alpha-galactosidase A (AGA) enzyme.

It is a multi-systemic and life-threatening condition that is one of the most common lysosomal storage diseases after the Gaucher Disease. It is characterized by specific neurological, cutaneous, renal, cardiovascular, cochleovestibular, and cerebrovascular manifestations. The symptoms include Chronic pain, usually a burning or tingling sensation in the hands and feet. The pain sometimes briefly becomes more intense, requiring medication to bring it down to manageable levels. 

Fabry Disease Emerging Therapy Assessment:

The current emerging landscape for Fabry disease mainly comprising of Phase II and Phase III candidate drugs. The key players for phase II and III clinical development are Lucerastat (Idorsia Pharmaceuticals), Pegunigalsidase alfa (Protalix Biotherapeutics), AVR-RD-01 (Avrobio), Venglustat (Sanofi Genzyme), ST-920 (Sangamo Therapeutics), 4D-310 (4D Molecular Therapeutics), and others.

Fabry Disease Key Companies:

  1. Safoni Genzyme

  2. Idorsia Pharmaceuticals

  3. Protalix Biotherapeutics

  4. Sangamo Therapeutics

  5. 4D MolecularTherapeutics

Fabry disease Therapies covered in the report include:

  1. Venglustat

  2. Lucerastat

  3. PRX- 102

  4. ST 920

  5. 4D-310

 

Report Highlights:

  1. A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Fabry disease.

  2. In the coming years, the Fabry disease market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world, expanding the size of the market to enable the drug manufacturers to penetrate more into the market.

  3. The companies and academics are working to assess challenges and seek opportunities that could influence Fabry disease Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  4. A detailed portfolio of major pharma players who are involved in fueling the Fabry disease treatment market. Several potential therapies for Fabry disease are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Fabry disease market size in the coming years. 

  5. Our in-depth analysis of the Fabry disease pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Table of Contents

  1. Report Introduction

  2. Fabry Disease

  3. Fabry disease Current Treatment Patterns

  4. Fabry disease – DelveInsight’s Analytical Perspective

  5. Therapeutic Assessment

  6. Fabry disease Late Stage Products (Phase-III)

  7. Fabry disease Mid Stage Products (Phase-II)

  8. Early Stage Products (Phase-I)

  9. Pre-clinical Products and Discovery Stage Products

  10. Inactive Products

  11. Dormant Products

  12. Fabry disease Discontinued Products

  13. Fabry disease Product Profiles

  14. Fabry disease Key Companies

  15. Fabry disease Key Products

  16. Dormant and Discontinued Products

  17. Fabry disease Unmet Needs

  18. Fabry disease Future Perspectives

  19. Fabry disease Analyst Review 

  20. Appendix

  21. Report Methodology

*The table of contents is not exhaustive; the final content may vary.

Related Reports: 

Fabry disease Market

DelveInsight’s “Fabry disease Market Insights, Epidemiology and Market Forecast – 2030” report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology as well as the Fabry disease Market size and shares analysis for the 7MM (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Fabry disease Epidemiology

DelveInsight’s Fabry disease – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Fabry disease in the 7MM (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Contact Info:

Kritika Rehani

DelveInsight Business Research

Email: [email protected]

Phone No: +91-9650213330

Connect With Us at:

LinkedIn | Facebook | Twitter

Healthcare Blog

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/ghaziabadonline/dispurnewsflash.com/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7